Pitcairn Co. bought a new stake in shares of Inogen, Inc. (NASDAQ:INGN – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,618 shares of the medical technology company’s stock, valued at approximately $86,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Inogen by 4.9% during the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock valued at $11,492,000 after purchasing an additional 65,954 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Inogen by 26.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 285,176 shares of the medical technology company’s stock valued at $1,566,000 after purchasing an additional 59,446 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Inogen by 347.2% during the fourth quarter. Federated Hermes Inc. now owns 265,485 shares of the medical technology company’s stock valued at $1,458,000 after acquiring an additional 206,125 shares during the period. Tocqueville Asset Management L.P. raised its holdings in shares of Inogen by 27.3% during the first quarter. Tocqueville Asset Management L.P. now owns 93,350 shares of the medical technology company’s stock valued at $753,000 after acquiring an additional 20,000 shares during the period. Finally, Stokes Family Office LLC acquired a new stake in shares of Inogen during the first quarter valued at approximately $351,000. 89.94% of the stock is owned by institutional investors and hedge funds.
Inogen Stock Up 3.2 %
Shares of INGN opened at $9.70 on Friday. The company’s 50 day moving average price is $8.46 and its 200 day moving average price is $7.68. Inogen, Inc. has a 52 week low of $4.13 and a 52 week high of $10.64.
Insider Buying and Selling at Inogen
In other Inogen news, EVP Jason Somer sold 10,000 shares of Inogen stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $8.56, for a total value of $85,600.00. Following the completion of the sale, the executive vice president now directly owns 4,452 shares in the company, valued at $38,109.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.99% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their price target on shares of Inogen from $6.00 to $7.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. StockNews.com downgraded shares of Inogen from a “hold” rating to a “sell” rating in a research report on Friday, July 19th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.
Get Our Latest Report on Inogen
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading
- Five stocks we like better than Inogen
- What is the Dow Jones Industrial Average (DJIA)?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Trading Halts Explained
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGN – Free Report).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.